The Lancet Haematology
Fecha de publicación: 8 May 2019
Autores: Daniel A Mulrooney, MD., Geehong Hyun, PhD., Prof Kirsten K Ness, PhD., Nickhill Bhakta, MD., Prof Ching-Hon Pui, MD., Matthew J Ehrhardt, MD., et al.
Background: Treatment for childhood acute lymphoblastic leukemia has evolved over the past five decades, with moderation of traditional chemotherapy and radiotherapy and the introduction of targeted immune-based and cellular-based therapies. The affect of these changes on late health outcomes has not been assessed. Using data from the The St Jude Lifetime (SJLIFE) Cohort, we aimed to characterise the magnitude of morbidity and patterns of late health outcomes among survivors of childhood acute lymphoblastic leukaemia treated over time.Leer más